VolitionRx Highlights a Transformational Year: Clinical Validation, Commercial Partnerships, and Potential Upcoming Milestones
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
VolitionRx (VNRX) highlighted clinical validation and commercial partnership progress across its diagnostic platforms, alongside revenue growth and reduced convertible debt. Revenue for the nine months ended September 30, 2026, reached $3.0 million, up 134% year over year; operating costs fell 13% and operating loss fell 24%. Convertible note debt declined by over $5.0 million since June 30, leaving approximately $0.7 million of principal.
Capture-Seq detected 94% of stage I and 96% of stage II cancers in a blinded 81-subject cohort. Nu.Q NETs is being evaluated in France's government-funded sepsis program. Fujifilm's supply agreement expanded to feline testing. Volition expects publication of its feline manuscript to subsequently unlock a $5 million milestone payment. Licensing discussions involve more than a dozen diagnostic and liquid biopsy companies; a French lung cancer reimbursement submission is expected this quarter.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointConvertible note debt declined by over $5.0 million since June 30, 2026. 69% of market cap
- Moderate pointRevenue reached $3.0 million for the nine months ended September 30, 2026, up 134% year over year.
- Moderate pointYear-to-date operating costs fell 13%.
- Moderate pointYear-to-date operating loss fell 24%.
- Moderate pointCapture-Seq detected 94% of stage I and 96% of stage II cancers in a blinded 81-subject cohort.
- Moderate pointPeer-reviewed sepsis data showed Nu.Q NETs H3.1 independently predicts 28-day mortality and need for kidney replacement therapy.
- Moderate pointFrance's €6.3 million (~$7.3 million) DETECSEPS program is evaluating Nu.Q NETs as its sole biomarker. 1× market cap
- Moderate pointFujifilm supply agreement expanded to cats in November, allowing development and use of the Nu.Q Vet Feline Test.
- Moderate pointFirst automated Nu.Q Vet Cancer Test for dogs launched with Fujifilm Vet Systems.
- Moderate point. Forward-looking: it has not happened yet and may not happen.French Nu.Q Lung Cancer reimbursement submission is being prepared with Hospices Civils de Lyon, expected this quarter.
7 minor points
- Minor pointCapture-Seq overall sensitivity was 93% at 95% specificity in that cohort, measuring detection and correct identification of controls.
- Minor pointFinger-prick prototype showed high correlation with the CE-marked automated assay in intensive-care sepsis patients.
- Minor point674-patient trauma study linked elevated nucleosome levels with trauma and subsequent complications.
- Minor pointFeline prototype detected 86% of feline lymphomas at 97% specificity.
- Minor point. Forward-looking: it has not happened yet and may not happen.Licensing discussions with more than a dozen companies support Volition's plans for further licensing and co-development agreements.
- Minor point. Forward-looking: it has not happened yet and may not happen.Broader NETs licensing agreements are potential milestones with current partners, which include Sysmex and Werfen.
- Minor point. Forward-looking: it has not happened yet and may not happen.Routine clinical use of Nu.Q NETs in Europe is a potential upcoming milestone.
Negative
- Major point. Forward-looking: it has not happened yet and may not happen.$5 million feline milestone payment is expected to follow manuscript publication; the manuscript remains in peer review. 69% of market cap
- Moderate pointMissionpharma agreement remains a non-binding letter of intent; a definitive finger-prick sepsis test agreement is a potential milestone.
- Moderate pointApproximately $0.7 million of convertible note principal remains outstanding.
News Explained
Volition has signed a non-binding letter of intent with Missionpharma to develop and launch its finger-prick sepsis test worldwide; moving to a definitive agreement remains an upcoming milestone, so the release describes a proposed collaboration rather than a completed commercial agreement.
Key Figures
- Year-to-date revenue
- $3.0 million
- Through September 30, 2026
- Revenue growth
- 134%
- First nine months of 2026 vs. first nine months of 2025
- Convertible note debt reduction
- Over $5.0 million
- Since June 30, 2026
- Remaining convertible note principal
- Approximately $0.7 million
- Current amount reported in the update
- Stage I and II cancer detection
- 94% (stage I); 96% (stage II)
- Blinded validation cohort of 81 subjects
- Overall sensitivity and specificity
- 93% sensitivity at 95% specificity
- Capture-Seq blinded validation cohort
- Feline lymphoma detection
- 86% at 97% specificity
- Feline prototype
- Potential milestone payment
- $5 million
- Expected to be unlocked by publication of the feline manuscript
Previous Partnership Reports
-
Sysmex collaboration optimized Nu.Q NETs H3.1 assay; current update cites broader agreements as potential milestones.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
netosis medical
liquid biopsy medical
lateral flow technical
convertible note financial
venous thromboembolism medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Peer-reviewed validation in sepsis, >
- Volition is in discussions with more than a dozen of the world's leading diagnostic and liquid biopsy companies to licence its proprietary platform protected by over 70 patents.
- Volition's model is to co-develop with third parties and license its technology for upfront and milestone payments, royalties and other recurring revenue, while keeping its own costs low.
Nu.Q® NETs: Sepsis and NETosis
- Landmark peer-reviewed validation: Critical Care Medicine published data, with an accompanying editorial, showing Nu.Q® NETs H3.1 independently predicts 28-day mortality and need for kidney replacement therapy in sepsis and septic shock.
- Sole biomarker in
France's DETECSEPS program: launched in September, this€6.3 million (~ ) government-funded program is evaluating Nu.Q® NETs in emergency departments potentially to become part of the national screening test for Sepsis.$7.3 million
- Finger-prick test: Volition's rapid lateral flow prototype showed high correlation with its CE-marked automated assay in ICU sepsis patients, opening the door to testing outside central laboratories. LOI with Missionpharma to develop and launch worldwide.
- New indications: a Mayo Clinic study of 674 trauma patients demonstrated that nucleosome levels, as measured by Volition's Nu.Q®H3.1 and Nu.Q®H3R8 Citrulline are elevated in people that have experienced a traumatic event, and are even higher in those patients that go on to have complications from the trauma. H3.1 levels in healthy people were 22.3 ng/ml, those with trauma were 359.7 and those that went on to get Venous Thromboembolism (VTE) were 828.4, over 37 times the level in healthy subjects. In our view, an ability to predict VTE (blood clots) in trauma patients with a simple blood test could be extremely clinically useful.
Nu.Q® Cancer and Capture-Seq™
- >
95% of early-stage cancers detected: in a blinded validation cohort of 81 subjects (colorectal and lung cancer patients and healthy controls), Capture-Seq™ detected94% of stage I and96% of stage II cancers, with93% overall sensitivity at95% specificity.
- First peer-reviewed Capture-Seq™ paper published in August; early stage I detection data presented at the ESMO MAP conference in September.
- Lung cancer: new prognostic and risk-stratification data; reimbursement submission for Nu.Q® Lung Cancer in
France being prepared with Hospices Civils deLyon , expected to be submitted this quarter.
Nu.Q® Vet
- Third species: the feline prototype detected
86% of feline lymphomas at97% specificity; the manuscript is in peer review and publication is expected to subsequently unlock a milestone payment.$5 million
- Fujifilm agreement expanded to include cats: in November, Volition expanded its supply agreement with Fujifilm Vet Systems in
Japan to allow the development and use of the Nu.Q® Vet Feline Test, extending the potential use of Nu.Q® technology toJapan's almost nine million cats. Volition expects this to be the world's first simple, affordable blood-based liquid biopsy test for feline cancer.
- First automated Nu.Q® Vet Cancer Test launched with Fujifilm Vet Systems for dogs.
A Stronger Financial Position
- Revenue growth: year-to-date revenue through September 30, 2026, of
, up$3.0 million 134% on the first nine months of 2025.
- Lower costs: year-to-date operating costs down
13% and operating loss down24% .
- Convertible note debt reduced by over
since June 30, 2026. Remaining convertible note principal is approximately$5.0 million .$0.7 million
What Comes Next
Upcoming potential milestones include:
- Publication of the feline manuscript anticipated subsequently to unlock
milestone payment;$5 million - Further licensing, and co-development agreements across multiple pillars;
- Broader agreements with some of our current NETs licencing partners, which currently include Sysmex and Werfen;
- Submission of the Nu.Q® Lung Cancer reimbursement application in
France ; - Advancement of the DETECSEPS program;
- Routine use in a clinical setting in
Europe of the Nu.Q® NETs test; - Moving to a definitive agreement with Missionpharma, with which Volition signed a non-binding Letter of Intent in October for its finger-prick sepsis test.
Cameron Reynolds, President and Group Chief Executive Officer, said:
"2026 has been a year of validation and progress. Independent peer-reviewed data now support Nu.Q® across sepsis and NETosis, cancer and animal health, which is driving our licencing discussions worldwide with a range of very large companies. Each of our key pillars targets a multi-billion-dollar market, and we only need a few of these agreements to be finalised to transform Volition commercially. At the same time, we have cut costs and substantially reduced our debt. Our focus now is converting this progress into more signed agreements."
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.
The contents found at Volition's website address, www.volition.com, are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries: Ellen Amonoo, Volition, mediarelations@volition.com
Safe Harbor Statement
Statements contained in this press release and made on the related conference call may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are those that are not statements of historical fact and instead address predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "continue," "project," "could," "would," "should," "may," "will" and similar expressions identify such statements.
These forward-looking statements relate to, among other topics, Volition's expectations regarding revenue opportunities and growth; the effectiveness and availability of its blood-based diagnostic, prognostic and disease monitoring tests; its ability to develop and successfully commercialize such test platforms for the early detection and monitoring of cancer and other diseases; its expectations regarding future publications and the related milestone payment; the timing and outcome of its reimbursement submission in France and the DETECSEPS program; estimates of addressable markets; its cost-reduction plans; its liquidity, capital needs and ability to fund operations; and its success in securing, and the terms of, licensing and/or distribution or other agreements with third parties, including a definitive agreement with Missionpharma.
Forward-looking statements are based on current expectations, estimates and projections about Volition's business, in part on assumptions made by management. They are not guarantees of future performance and involve risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those anticipated. These risks and uncertainties include, without limitation: Volition's need for additional financing, which may not be available on acceptable terms or at all, the uncertain timing of publication of Volition's feline lymphoma study; the timing and outcome of Volition's reimbursement submission in France and of the DETECSEPS program; Volition's dependence on key collaborators and distributors, including Sysmex Corporation, Werfen, Missionpharma and Hospices Civils de Lyon; the assumptions underlying Volition's addressable market estimates; the results of studies testing the efficacy of Volition's tests; failure to develop and commercialize its products, which may prevent it from executing its plan of operations; failure to obtain necessary regulatory clearances or approvals; failure to achieve healthcare system or insurance reimbursement; failure of the marketplace to accept its products; failure to secure adequate intellectual property protection; the highly competitive and rapidly evolving nature of the diagnostics and disease monitoring market, which may render its products obsolete; downturns in domestic and foreign economies; and other risks identified in Volition's most recent Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and other documents filed with the Securities and Exchange Commission.
Forward-looking statements are made as of the date hereof and, except as required by law, Volition undertakes no obligation to update them to reflect future events or circumstances.
Nu.Q®, Nucleosomics™, Capture-PCR™, Capture-Seq™ and rNuQ™ and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release or associated video or link are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.
View original content to download multimedia:https://www.prnewswire.com/news-releases/volitionrx-highlights-a-transformational-year-clinical-validation-commercial-partnerships-and-potential-upcoming-milestones-302942283.html
SOURCE VolitionRx Limited
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much did VolitionRx revenue grow in the first nine months of 2026?
VolitionRx revenue reached $3.0 million for the nine months ended September 30, 2026, up 134% from the first nine months of 2025. Year-to-date operating costs fell 13%, while operating loss fell 24%.
What did VolitionRx Capture-Seq show in its blinded cancer validation cohort?
Capture-Seq detected 94% of stage I and 96% of stage II cancers in a blinded validation cohort of 81 subjects. The cohort included colorectal and lung cancer patients and healthy controls. Overall sensitivity was 93% at 95% specificity.
What is the status of VolitionRx's Missionpharma finger-prick sepsis test agreement?
VolitionRx signed a non-binding letter of intent in October with Missionpharma to develop and launch its finger-prick sepsis test worldwide. Moving to a definitive agreement is an upcoming potential milestone.
What did the Mayo Clinic trauma study show about VolitionRx's Nu.Q tests?
The study of 674 trauma patients found elevated nucleosome levels after trauma, with higher levels among patients who subsequently developed complications. H3.1 levels were 22.3 ng/ml in healthy people, 359.7 ng/ml in those with trauma and 828.4 ng/ml in those who subsequently developed venous thromboembolism, or blood clots.